Baoji Pharmaceutical (02659) included in the MSCI Global Index components, innovative research and development capabilities recognized globally.

On May 14, 2026, Baoji Pharmaceutical Industry (02659) announced that, according to the index review results published by MSCI on May 12, 2026, the company has successfully been included in the MSCI Global Small Cap Indexes. The relevant adjustments will officially take effect after the close of trading on May 29, 2026. The MSCI Global Small Cap Indexes are compiled by MSCI Inc., aiming to measure the performance of representative and investable small and medium-sized companies in the global market. The MSCI index system is one of the most influential index systems in the world, with global institutional investor funds tracking MSCI indexes exceeding $17 trillion, covering various professional investment institutions such as sovereign wealth funds, pension funds, mutual funds, and exchange-traded funds (ETFs). Selection criteria include market capitalization, liquidity, industry distribution, and corporate governance, among other core indicators. Being included in this index marks an increase in Baoji Pharmaceutical Industry's visibility and influence in the global capital market, which will help the company's stocks attract more attention from international investors, potentially bringing incremental passive funds for allocation, and further enhancing the market liquidity, trading activity, and international visibility of the shares.